Results 261 to 270 of about 152,178 (350)

Oral Bioavailability of Monoclonal Antibody. [PDF]

Pharmaceutics
Verma A, Wu S, Shah DK.
europepmc   +1 more source

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis. [PDF]

Nat Commun
Strickler JH, Cercek A, Siena S, André T, Ng K, Van Cutsem E, Wu C, Paulson AS, Hubbard JM, Coveler AL, Fountzilas C, Kardosh A, Kasi PM, Lenz HJ, Ciombor K, Elez E, Bajor DL, Cremolini C, Sanchez F, Nayeri M, Feng W, Bieda M, Bekaii-Saab TS.   +22 more
europepmc   +1 more source

Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice [PDF]

Giulia Notini, Matteo Maria Naldini, Lorenzo Sica, Giulia Viale, Alessia Rognone, Stefania Zambelli, Patrizia Zucchinelli, Marta Piras, Carlo Bosi, Marco Giovanni Mariani, D. Aldrighetti, Giampaolo Bianchini, Luca Licata   +12 more
openalex   +1 more source

Is there hope for HER2-positive colorectal cancer with Trastuzumab? A review of current evidence. [PDF]

Ann Med Surg (Lond)
Olatunji G, Aderinto N, Kokori E, Awoyinfa M, Ajimotokan O, Ajayi JO, Rao NN, Temidayo AO, Napoleon T, Ezeano C, Bukky SO, Nortey-Adom EE, Karbo SA, Abraham IC.   +13 more
europepmc   +1 more source

Antibody-Based Therapeutics in Breast Cancer: Clinical and Translational Perspectives. [PDF]

Antibodies (Basel)
Balata A, Pogoda K.
europepmc   +1 more source

Cardiovascular risk factors and cardiac dysfunction in people with HIV and breast cancer: an observational cohort study in Botswana. [PDF]

Cardiooncology
Afari H, Xia C, Mwita J, Moshomo T, Huang A, Shaikh M, Motlhwa SW, Ralefala T, Vuylsteke P, Dryden-Peterson S, Hsue PY, Gross R, Mosepele M, Ky B, Martei YM.   +14 more
europepmc   +1 more source

Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy

, 2019
Mamoru Takada, Tsunehiko Higuchi, Katsunori Tozuka, Hiroyuki Takei, Masayuki Haruta, Junko Watanabe, Fumio Kasai, Kenichi Inoue, Masafumi Kurosumi, Masaru Miyazaki, Aiko Sato‐Otsubo, Seishi Ogawa, Yasuhiko Kaneko   +12 more
openalex   +1 more source

Durable clinical and metabolic response to Trastuzumab Deruxtecan in heavily Pretreated male HER2-low metastatic breast cancer: a case report. [PDF]

Oxf Med Case Reports
Lamsyah O, Belrhali I, Al Harrak Y, Bel Lakhdar M, Lkhoyaali S, Boutayeb S, El Ghissassi I, M'rabti H, Errihani H.   +8 more
europepmc   +1 more source

Impact of antiemetic prophylaxis on reducing trastuzumab deruxtecan dose modifications in HER2+/HER2-low breast cancer. [PDF]

Future Oncol
Shin J, Kim JY, Ahn HK, Ahn JS, Park YH.
europepmc   +1 more source